Trials / Withdrawn
WithdrawnNCT03242967
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Phase 3, Randomized, Open Label, Active Controlled Study Evaluating the Efficacy and Safety of Three Times Per Week (TIW) Oral Dosing of Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILO2GY)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Akebia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 3 Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vadadustat | Oral tablet |
| DRUG | Darbepoetin alfa | subcutaneous or intravenous |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2018-02-12
- Completion
- 2018-02-12
- First posted
- 2017-08-08
- Last updated
- 2018-11-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03242967. Inclusion in this directory is not an endorsement.